- Open Access
miR-449 inhibits cell proliferation and is down-regulated in gastric cancer
- Tony Bou Kheir†1,
- Ewa Futoma-Kazmierczak†2,
- Anders Jacobsen3,
- Anders Krogh3,
- Linda Bardram4,
- Christoffer Hother5,
- Kirsten Grønbæk5,
- Birgitte Federspiel6,
- Anders H Lund1Email author and
- Lennart Friis-Hansen2Email author
© Kheir et al; licensee BioMed Central Ltd. 2011
- Received: 7 September 2010
- Accepted: 18 March 2011
- Published: 18 March 2011
Gastric cancer is the fourth most common cancer in the world and the second most prevalent cause of cancer related death. The development of gastric cancer is mainly associated with H. Pylori infection leading to a focus in pathology studies on bacterial and environmental factors, and to a lesser extent on the mechanistic development of the tumour. MicroRNAs are small non-coding RNA molecules involved in post-transcriptional gene regulation. They are found to regulate genes involved in diverse biological functions and alterations in microRNA expression have been linked to the pathogenesis of many malignancies. The current study is focused on identifying microRNAs involved in gastric carcinogenesis and to explore their mechanistic relevance by characterizing their targets.
Invitrogen NCode miRNA microarrays identified miR-449 to be decreased in 1-year-old Gastrin KO mice and in H. Pylori infected gastric tissues compared to tissues from wild type animals. Growth rate of gastric cell lines over-expressing miR-449 was inhibited by 60% compared to controls. FACS cell cycle analysis of miR-449 over-expressing cells showed a significant increase in the sub-G1 fraction indicative of apoptosis. ß-Gal assays indicated a senescent phenotype of gastric cell lines over-expressing miR-449. Affymetrix 133v2 arrays identified GMNN, MET, CCNE2, SIRT1 and CDK6 as miR-449 targets. Luciferase assays were used to confirm GMNN, MET, CCNE2 and SIRT1 as direct targets. We also show that miR-449 over-expression activated p53 and its downstream target p21 as well as the apoptosis markers cleaved CASP3 and PARP. Importantly, qPCR analyses showed a loss of miR-449 expression in human clinical gastric tumours compared to normal tissues.
In this study, we document a diminished expression of miR-449 in Gastrin KO mice and further confirmed its loss in human gastric tumours. We investigated the function of miR-449 by identifying its direct targets. Furthermore we show that miR-449 induces senescence and apoptosis by activating the p53 pathway.
- Gastric Cancer
- Pylorus Infection
- Gastric Cancer Cell Line
- MKN74 Cell
- SNU638 Cell
Gastric cancer is among the five most common cancers in the world and the second most prevalent cause of cancer-related deaths . It is mainly, but not exclusively, caused by H. Pylori infection  as not all of H. Pylori infected persons develop tumours . Other factors involved in the development of gastric cancer include the degree and type of the inflammatory response  as well as the levels of the Gastrin hormone [4, 5]. Several studies have shown that both hypergastrinemia [6, 7] and the lack of Gastrin  contribute to the pathogenesis of gastric cancer. Achlorhydria is a common feature of mouse models prone to developing metaplasia and cancer [6, 8, 9]. Gastrin knockout mice are achlorhydric , favouring a bacterial gastric overgrowth [11, 12], and chronic bacterial gastric infections lead to gastric metaplasia which may progress into gastric cancer [6, 12].
Since their discovery microRNAs, have been found implicated in a very wide range of normal and pathological processes . MicroRNAs exert their regulatory functions posttranscriptionally by binding to partly complementary sequence motifs predominantly in the 3' UTR of target mRNAs resulting in mRNA destabilization and translational repression . From a biological point of view, microRNAs are challenging objects to study as they regulate cohorts of target genes, which are not readily identified. From a therapeutical point of view, microRNAs are highly interesting as several studies have demonstrated the power of microRNAs as biomarkers and initial preclinical studies have established that microRNAs may be therapeutically targeted in vivo .
Profiling studies have evidenced microRNA deregulation in a broad spectrum of diseases including all major cancers . MicroRNAs likely affect tumourigenic processes at two levels. Firstly, several studies have established pro-oncogenic or tumour-suppressive roles of individual microRNAs firmly linking these to cancer etiology as exemplified by miR-155, miR-10b and miR-21 [17–19]. Secondly, the microRNA regulatory system per se appears to have tumour suppressive functions as genetic ablation of key microRNA biogenesis factors, such as Dicer, strongly increase cancer susceptibility  and loss of function mutations have been identified in important microRNAs processing factors in human tumours [21–23].
In this study, we address the importance of microRNAs in gastric cancer taking advantage of the Gastrin knockout mouse model and H. pylori infection of wild type mice. We identify miR-449 as significantly down-regulated or lost in mouse models of gastric cancer as well as in primary human gastric tumours. Identification of mRNA targets reveals that this microRNA likely exerts tumour suppressive functions through the concerted regulation of a cohort of cancer-associated cell-cycle regulators including MET, GMNN, CCNE2, SIRT1, and HDAC1.
Three different age groups (12-16 weeks, 1 year or 1½ years) of wild type (wt) or Gastrin knockout (KO) mice were used. All mice were on a mixed 129/SvJ, C57BL/6J background, backcrossed at least four times to C57BL/6J . The mice were kept under specific pathogen-free conditions and monitored according to the Federation of European Laboratory Animal Science Associations recommendation  with 12 h light, 12 h dark cycles.
H. pylori infection
C57BL6/J mice (n = 10) were inoculated with a non-mouse-adapted clone of H. Pylori strain 67:21, originally isolated from an antral biopsy obtained from a Swedish female with gastric ulcer. The strain is VacA+ and contains the entire Cag pathogenicity island (PAI) with genetic stability in the Cag PAI . The mice were inoculated every second day (three times) during a 5-day period. DNA was extracted and analyzed for the presence of helicobacter species using a semi-nested polymerase chain reaction-denaturing gradient gel electrophoresis assay, specific for the genus helicobacter, as described previously . A matched group of uninfected C57BL6/J mice were used as controls.
The stomachs of all mice were dissected into fundus and antrum prior to RNA extraction. All animal experiments were approved by the Danish Animal Welfare Committee (2005/562-40) and the Danish Forest and Nature Agency (20010077355/6).
Mice antrum sections
Mice were sacrificed by cervical dislocation. The antrum was removed, washed gently in ice-cold PBS, frozen in liquid nitrogen and stored at -80°C until RNA extraction.
Clinical samples analyses
Biopsies from gastric cancer and the adjacent normal tissues were obtained from patients undergoing surgery for gastric cancer at the Department of Gastrointestinal Surgery, Rigshospitalet. The inclusion took place in July to December 2008 and all patients provided signed, informed consent (Ethical committee approval H-B-2008-049) and Danish Data Protection Agency (2008-41-2138). The biopsies were placed in RNAlater (Ambion) in the operating room and subsequently frozen at -80°C until RNA extraction.
RNA extraction and qPCR analyses
RNA was extracted using TRIzol (Invitrogen) according to manufacturer. miRNA expression profile was assessed using Taqman miRNA assays (Applied biosystems) for hsa/mmu-miR-449a and b, hsa/mmu-miR-34a, b and c and rnu44 or hsa/mmu-miR-191. Primer sequences for Affymetrix targets validation are listed in additional file 1, table S1.
SNU638 and MKN74 were grown in RPMI-1640 (Gibco) with 10% FBS (Hyclone), 100U/ml penicillin and 100 μg/ml streptomycin (Invitrogen) and incubated at 37°C in 5% CO2. HCT116 cells (wt and p53-/- were grown in McCoy's 5A (Gibco) with 10% FBS (Hyclone), and 100U/ml penicillin and 100 μg/ml streptomycin (Invitrogen) and incubated at 37°C in 5% CO2. HEK293 and MEF cells (wt and p53-/-) were grown in DMEM (Gibco) with 10%FBS (Hyclone), 100U/ml penicillin and 100 μg/ml streptomycin (Invitrogen) and incubated at 37°C with 5% CO2.
miRNA precursors and siRNA
miRNA precursors were purchased from Ambion, hsa-miR-449a (PM11521), hsa-miR-449b (PM11127) and hsa-miR-34a (PM11030).
Cell growth analyses
SNU638 cells were seeded in 24-well plates and transfected the following day with 50nM miRNA duplex or siRNA using Lipofectamine 2000 (Invitrogen). Cells were fixed at indicated time points in 4% paraformaldehyde, stained in a 0.1% crystal violet solution, and resuspended in 10% acetic acid. Sample absorbance was measured at 620 nm.
Cell cycle FACS analyses
SNU638 and MKN74 cells were seeded at 2 × 106 cells per 10cm plate and transfected with 50nM miRNA duplex (Ambion) using Lipofectamine 2000 (Invitrogen). Cells were harvested 48 and 72 hours post-transfection, stained for DNA content using propidium iodide (PI) and analyzed on a FACS Calibur flow cytometer (Becton-Dickinson). Briefly, cells were harvested by trypsinization and washed once with PBS before fixing over night in 70% EtOH. To stain the DNA, cells were pelleted, re-suspended in 100 μl EtOH and stained for 1 hour with 300 μl PI solution (0.05mg/ml PI, 20 μg/ml RNAse A in 0.1%BSA).
SNU638 cells were seeded at 400.000 cells per 6-well-plate and transfected with 50nM miRNA duplex (Ambion) using Lipofectamine 2000 (Invitrogen). Four days post-transfection, cells were washed in PBS and fixed for 5 minutes at room temperature in 2% formaldehyde/0.2% glutaraldehyde. Cells were washed twice in PBS pH6.0 before being stained with fresh senescence associated β-Gal stain solution (1mg/ml 5-bromo-4-chloro-3-indolyl-βD-galactoside (X-Gal), 0.12mM K3Fe[CN]6, 0.12mM K4Fe[CN]6, 1mM MgCl2 in PBS pH6.0) overnight at 37°C without CO2 supply. Cells were washed once in PBS (pH6.0) and observed under the microscope.
Antibodies and western blot analyses
SNU638 were seeded at 2 × 106 cells per 10 cm plate, transfected twice on two successive days with 50nM miRNA duplexes using Lipofectamine 2000 according to manufacturer (Invitrogen). Cells were harvested by trypsinization, washed once with PBS and lysed in RIPA buffer (150mM NaCl, 0.5% Sodium Deoxycholate, 0.1% SDS, 1% Igepal, 50mM Tris-HCl pH8, 2mM EDTA) supplemented with 1mM DTT, 1mM Pefabloc, 1mM NaV3, 10mM NaF and 1X complete mini protease inhibitor cocktail tablets. 25 μg of protein/lane were resolved on 4-20% NuPAGE Bis-Tris gels (Invitrogen) and transferred to a nitrocellulose membrane. Primary antibodies used were MET (Cell Signal 4560), MYC (Cell Signal 9402), GMNN (Santa Cruz Sc-53923), VCL (Sigma V9131), TP53 (Santa Cruz Sc-126), CDKN1A (Santa Cruz Sc-6246), CDK6 (Santa Cruz Sc-177), HDAC1 (Santa Cruz Sc-7872), CCNE2 (Cell Signal 4132), TUBB (Abcam ab11304), PARP (Cell Signal 9542) and Cleaved CASP3 (Cell Signal 9661).
Small RNAs (< 200 nt) were isolated with Invitrogen PureLink miRNA Isolation Kit from fundic and antral tissue from 1) Gastrin KO mice and age and sex matched C57BL6/J control mice, and 2) C57BL6/J mice infected with H. Pylori and uninfected age and sex matched C57BL6/J control mice, (n = 4 for each group). The quality of isolated small RNAs was determined using the Small RNA Assay on an Agilent Bioanalyzer. 500ng of small RNA was labelled with Genisphere FlashTag Kit and hybridized to Invitrogen NCode Multi-Species miRNA Microarray V2 in a Maui hybridization station. Processed slides were scanned in an Agilent DNA microarray scanner. Resulting images was analyzed and ratio of median normalized using GenePix Pro 6.0. Four biological replicates were used for each comparison. Samples were hybridized to four arrays in a dual colour dye swap microarray experimental design. BRB ArrayTools were used for fold change and statistical calculations. Selected miRNA data from the array analysis were validated using TaqMan real-time PCR miRNA assays. Data will be deposited at ArrayExpress upon acceptance.
SNU638 were transfected with 50 nM of miR-34a or miR-449b duplexes with siGLO siRNA used as negative control. Total RNA was extracted 24 hours post-transfection using TRIzol reagent. Affymetrix microarray analysis (HG-U133 Plus 2.0 human) was performed at the Microarray Center, Rigshospitalet, Copenhagen University Hospital. Experiments were run in either triplicates or quadruplicates. Data will be deposited at ArrayExpress upon acceptance.
Vectors construction and reporter assays
The 3'UTRs of HDAC1, SIRT1, MET, GMNN and CCNE2 holding miR-449 binding sites were cloned downstream of the luciferase reporter in pMIR-REPORT vector system (Ambion). Quickchange site-directed mutagenesis kit (Stratagene) was used to induce two point mutations into the seed region. Mutagenesis primers sequences are listed in Additional file 1, table S1.
HEK293 cells were seeded in 96 well plates and transfected with 20nM miRNA precursor or scrambled siRNA control, 20-50ng of luciferase vector (pMIR-report) and 5ng of renilla vector (pRL-TK) using lipofectamine 2000 (Invitrogen). Cells were harvested 24 hours post transfection and luciferase activity was measured using Dual-Glo luciferase assay (Promega).
Microarray expression data was processed using the 'affy' package in BioConductor . Probe set intensities were summarized and quantile normalized using the BioConductor RMA and VSN packages. Differential expression was determined per probeset using a t-test. Probe sets were mapped to Ensembl transcripts (version 49) using mappings provided at BioMart. Probesets that mapped to two different Ensembl genes were discarded.
Evaluating global down-regulation of microRNA target genes
The 3'UTRs, 5'UTRs and coding sequences of the transcripts were scanned for matching 6mer, 7mer and 8mer miRNA seed sites (complementary to position 2-7, 2-8, and 2-9 of the miRNA). Global analysis of miRNA target down-regulation was evaluated using the longest 3'UTR sequence per gene to avoid bias introduced by genes with many transcript isoforms. We discarded transcripts with 3'UTR sequences shorter than 50 nt. To globally evaluate if miRNA target genes were down-regulated after miRNA transfection, we tested the null hypothesis that the expression change distribution of miRNA targets (having a 7mer target site) was equal to the distribution of all expressed genes without predicted target sites using the non-parametric Wilcoxon rank-sum test. A similar approach was used to evaluate down-regulation of genes with miRNA target sites in coding regions and 5'UTRs of mRNAs.
Exhaustive statistical assessment of words correlated with down-regulation
We used a previously published non-parametric rank-based statistic to exhaustively assess the correlation of word occurrences in 3'UTRs and the change in gene expression after miRNA transfection [28, 29]. Genes were sorted by expression change induced by transfection of miR-34a or miR-449b, and the correlation with down-regulation was tested for all words of length 5-7 (N = 21 504).
Students t-test with Welch's correction.
miR-449b is down regulated in the antrum of both Gastrin KO mice and H. pylori infected mice
miRNAs deregulated in Gastrin knockout mice
miRNAs deregulated in H.Pylori infected tissues
miR-449 inhibits cell cycle progression and induces senescence
The joint seed sequence of miR-449b and miR-34a induce highly correlated expression changes
To characterize the transcripts controlled by miR-449 and to see if miR-449 regulates different transcripts than miR-34a, SNU638 cells expression profiles were examined 24 hours post transfection of miR-449b or miR-34a and differentially expressed transcripts identified. We found that mRNAs with predicted miRNA target sites (7 mer seed site) in the 3'UTR were significantly down-regulated compared to mRNAs without predicted target sites after transfection of miR-449b (p < 1.2e-70, two-tailed Wilcoxon rank-sum test), (Additional file 1, figure S4a). mRNAs having predicted miRNA seed target sites in coding regions were also found to be significantly down-regulated (p < 9.9e-25), while mRNAs with sites in 5'UTRs were only marginally down-regulated (p < 5.3e-2). The expression changes induced by transfection of mature miR-449b and miR-34a were highly correlated despite divergence of the mature sequences outside the seed region (Pearson's correlation coefficient R = 0.94, p = 0), (Additional file 1, figure S4b). We exhaustively evaluated all oligonucleotides (words) of length 5-7 for correlation with down-regulation after miR-449b and miR-34a transfection (see methods). Consistent with many previous studies, this analysis revealed the shared miR-34a/449b seed site as the 3'UTR word most correlated with down-regulation in the two experiments (Additional file 1, figure S4c).
miR-449 regulates numerous cell cycle controllers
Hence, miR-449 directly targets cell cycle regulator genes consistent with a tumour suppressor function and with the cell cycle arrest observed upon miR-449 re-introduction into cancer cell lines.
miR-449 induces p53 expression but is not regulated by p53
Hence, we speculate that miR-449 induces apoptosis by inhibiting the histone deacetylase HDAC1 and SIRT1 leading to the p53 pathway activation thus the induction of apoptosis markers cleaved CASP3 and PARP.
miR-449 is down-regulated in human gastric cancers
Gastric cancer is a highly lethal malignancy with more than 21,500 new cases each year in the United States alone . The disease is often detected late and the 5-year survival rate is consequently below 20% . It is therefore important to understand the etiology and progression stages of the disease. The importance of the bacterial, environmental and host genetic risk factors in gastric carcinogenesis have been studied, however less is known about the molecular progression of the disease [37, 38]. Among others, p53 pathway inactivation is reported in 30-60% of gastric cancers [39, 40] and recent studies suggest H. pylori direct modulation of the p53 gene or its downstream targets . Another common alteration in gastric cancer is the perturbation of the cell cycle control via the over expression of Cyclin E1, which is associated with tumour aggressiveness and lymph node metastasis [42, 43]. In contrast to our current understanding of the role of tumour suppressors and cell cycle factors, the knowledge about the post transcriptional changes affecting gene expression in gastric cancer is still incomplete.
Using the Gastrin knockout mouse model for gastric cancer [6, 12], we identify 20 deregulated microRNAs of which 3 were more than 2-fold deregulated relative to their levels in normal gastric mucosa. As infection with H. pylori has been causally linked to gastric cancer [44, 45], we next examined changes in microRNA expression levels following infection of wild type mice with H. Pylori. Interestingly, miR-449b was the only miRNA significantly deregulated in both mouse models. To establish a causal relationship between miR-449 deregulation and cancer-relevant parameters, such as cell cycle regulation, apoptosis and senescence, we over-expressed miR-449 in gastric cancer cell lines and observed a significant down-regulation of proliferation coupled with up-regulation of the acidic beta-gal senescence marker and induction of apoptosis. Importantly, analyses of primary gastric tumours from patients clearly documented a tumour-specific down-regulation of miR-449 also in humans. Previously, a number of studies have demonstrated deregulation of miRNA in gastric cancer [46–50] and the importance of the entire microRNA system has been documented in both gastric and colon cancer by the presence of cancer-specific mutations in the key RISC components AGO2 and TNRC6A. Furthermore, microRNAs are likely of important prognostic value in gastric cancer [52–54]. The present study represents the first report demonstrating cancer-related down-regulation of miR-449 in both mouse models for gastric cancer and in primary human gastric tumours. Beside gastric cancer, the expression of miR-449 has also been found to be reduced in several cell lines  and in prostate cancer, where it was found to target HDAC1 and induce growth arrest following over-expression in prostate cancer cells . In contrast, the expression of miR-449 has been reported to be increased in endometrioid adenocarcinoma  and melanoma in young adult patients . The expression of miR-449 was also increased in skeletal muscle damage and regeneration .
To unveil molecular links between the loss of miR-449 and cancer progression or initiation we experimentally identified a number of direct mRNA targets using transcriptional profiling and extensive bioinformatics analysis. A series of the putative miR-449 targets were subsequently validated at endogenous level using western blotting and quantitative PCR and their direct regulation by miR-449 was established using heterologous reporter constructs and binding site-specific mutation studies. Prominent validated targets include CDK6, MYC, CCNE2, MET and GMNN and we furthermore validated the regulation of HDAC1 and SIRT1 also in gastric cancer cells. Hence, the cancer-specific loss or down-regulation of miR-449 in gastric cancer can likely be explained by the connection to key cell cycle regulators. During the search for miR-449 targets we also identified several growth factors (AREG, and KITLG) and growth factor receptors, such as MET, as targets. This suggests that deregulation of miR-449 not only leads to deregulated control of cell cycle proteins but also of growth factors and their receptors. Thus, another important property of miR-449 could be as a regulator of signals important for growth and migration/invasion.
Interestingly, miR-449 was recently shown to operate under the control of E2F1 [55, 60]. This is highly interesting as it places miR-449 at a key node in a feed-back loop in which E2F1 activates the transcription of miR-449 that in turn targets CDC25A and CDK6. Reduced levels of CDC25A and CDK6 decreases the phosphorylation of pRB and subsequently inhibits the release of E2F1 [55, 60, 61]. Hence, aside from the pro-oncogenic effects of up-regulation of MYC, MET, CCNE2 and other direct targets, loss of miR-449 may result in increased E2F1 activity.
Many of the direct mRNA targets for miR-449 identified in this study are also targets of miR-34a and miR-449 and miR-34a belong to the same family of miRNAs as they share the same seed sequence. In accordance, miR-34a has been demonstrated to act as an important tumour-suppressor miRNA and reduced expression of miR-34a has been reported for neuroblastoma  and many other cancers . In addition, the miR-34a gene is activated by p53 following DNA damage [30–33] and by ELK1 following over-expression of activated B-RAF .
In the present study, transcriptional profiling demonstrated that over-expression of miR-449 or miR-34a results in identical transcriptome changes. While this is underlining the dominant importance of the seed sequence in this type of over-expression study it also points to a limitation in the experimental approach. While miR-449 was clearly down-regulated or lost in the analyzed mouse tumour samples no clear tendency for loss or down-regulation of miR-34a was observed (data not shown). This indicates that these microRNAs may have more deviant functions in vivo than suggested by the over-expression studies.
Finally, we examined the relationship between the p53 tumour suppressor and miR-449. As miR-34a has been firmly placed downstream from p53 [30–33] it was relevant to test if the same was the case for miR-449. In agreement with other studies [55, 60], we did not observe a p53-dependent regulation of miR-449 in gastric cancer cells as well as in primary human and mouse fibroblasts. However, in agreement with previous findings for miR-34a, we find that miR-449 regulates the expression of p53 [31, 32] as over-expression of miR-449 resulted in a potent up-regulation of p53 subsequently resulting in activation of p21 and induction of apoptosis markers, such as cleaved CASP3 and PARP as previously reported .
In summary, we have found that miR-449 may act as a tumour suppressor and is lost in gastric cancer. Its re-introduction into cancer cell lines leads to inhibition of cell proliferation by targeting different cell cycle regulators. We also found that re-introduction of miR-449 induces senescence and apoptosis. Hence, this study further underlines the importance of miRNAs in cancer and points to an important function for miR-449 in gastric cancer.
We thank Mikkel Klausen for technical assistance and Disa Tehler for her comments on the manuscript. Work in the authors' laboratories is supported by The Danish National Research Foundation, The EC FP7 ONCOMIRS consortium (grant agreement number 201102. This publication reflects only authors' views. The commission is not liable for any use that may be made of the information herein), The Novo Nordisk Foundation, The Lundbeck Foundation, The Danish Cancer Society and the Danish National Advanced Technology Foundation.
- Smith MG, Hold GL, Tahara E, El-Omar EM: Cellular and molecular aspects of gastric cancer. World J Gastroenterol. 2006, 12: 2979-2990.PubMed CentralPubMedGoogle Scholar
- Kountouras J, Zavos C, Chatzopoulos D, Katsinelos P: New aspects of Helicobacter pylori infection involvement in gastric oncogenesis. J Surg Res. 2008, 146: 149-158. 10.1016/j.jss.2007.06.011View ArticlePubMedGoogle Scholar
- Polk DB, Peek RM: Helicobacter pylori: gastric cancer and beyond. Nat Rev Cancer. 2010, 10: 403-414. 10.1038/nrc2857PubMed CentralView ArticlePubMedGoogle Scholar
- Wang TC, Dangler CA, Chen D, Goldenring JR, Koh T, Raychowdhury R, Coffey RJ, Ito S, Varro A, Dockray GJ, Fox JG: Synergistic interaction between hypergastrinemia and Helicobacter infection in a mouse model of gastric cancer. Gastroenterology. 2000, 118: 36-47. 10.1016/S0016-5085(00)70412-4View ArticlePubMedGoogle Scholar
- Takaishi S, Tu S, Dubeykovskaya ZA, Whary MT, Muthupalani S, Rickman BH, Rogers AB, Lertkowit N, Varro A, Fox JG, Wang TC: Gastrin is an essential cofactor for helicobacter-associated gastric corpus carcinogenesis in C57BL/6 mice. Am J Pathol. 2009, 175: 365-375. 10.2353/ajpath.2009.081165PubMed CentralView ArticlePubMedGoogle Scholar
- Zavros Y, Eaton KA, Kang W, Rathinavelu S, Katukuri V, Kao JY, Samuelson LC, Merchant JL: Chronic gastritis in the hypochlorhydric gastrin-deficient mouse progresses to adenocarcinoma. Oncogene. 2005, 24: 2354-2366. 10.1038/sj.onc.1208407View ArticlePubMedGoogle Scholar
- Friis-Hansen L: Achlorhydria is associated with gastric microbial overgrowth and development of cancer: lessons learned from the gastrin knockout mouse. Scand J Clin Lab Invest. 2006, 66: 607-621. 10.1080/00365510600873894View ArticlePubMedGoogle Scholar
- Elso CM, Lu X, Culiat CT, Rutledge JC, Cacheiro NL, Generoso WM, Stubbs LJ: Heightened susceptibility to chronic gastritis, hyperplasia and metaplasia in Kcnq1 mutant mice. Hum Mol Genet. 2004, 13: 2813-2821. 10.1093/hmg/ddh307View ArticlePubMedGoogle Scholar
- Judd LM, Andringa A, Rubio CA, Spicer Z, Shull GE, Miller ML: Gastric achlorhydria in H/K-ATPase-deficient (Atp4a(-/-)) mice causes severe hyperplasia, mucocystic metaplasia and upregulation of growth factors. J Gastroenterol Hepatol. 2005, 20: 1266-1278. 10.1111/j.1440-1746.2005.03867.xView ArticlePubMedGoogle Scholar
- Friis-Hansen L, Sundler F, Li Y, Gillespie PJ, Saunders TL, Greenson JK, Owyang C, Rehfeld JF, Samuelson LC: Impaired gastric acid secretion in gastrin-deficient mice. Am J Physiol. 1998, 274: G561-568.PubMedGoogle Scholar
- Zavros Y, Rieder G, Ferguson A, Samuelson LC, Merchant JL: Genetic or chemical hypochlorhydria is associated with inflammation that modulates parietal and G-cell populations in mice. Gastroenterology. 2002, 122: 119-133. 10.1053/gast.2002.30298View ArticlePubMedGoogle Scholar
- Friis-Hansen L, Rieneck K, Nilsson HO, Wadstrom T, Rehfeld JF: Gastric inflammation, metaplasia, and tumor development in gastrin-deficient mice. Gastroenterology. 2006, 131: 246-258. 10.1053/j.gastro.2006.04.031View ArticlePubMedGoogle Scholar
- Kato M, Slack FJ: microRNAs: small molecules with big roles - C. elegans to human cancer. Biol Cell. 2008, 100: 71-81. 10.1042/BC20070078View ArticlePubMedGoogle Scholar
- Fabian MR, Sonenberg N, Filipowicz W: Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem. 2010, 79: 351-379. 10.1146/annurev-biochem-060308-103103View ArticlePubMedGoogle Scholar
- Petri A, Lindow M, Kauppinen S: MicroRNA silencing in primates: towards development of novel therapeutics. Cancer Res. 2009, 69: 393-395. 10.1158/0008-5472.CAN-08-2749View ArticlePubMedGoogle Scholar
- Croce CM: Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 2009, 10: 704-714. 10.1038/nrg2634PubMed CentralView ArticlePubMedGoogle Scholar
- Eis PS, Tam W, Sun L, Chadburn A, Li Z, Gomez MF, Lund E, Dahlberg JE: Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci USA. 2005, 102: 3627-3632. 10.1073/pnas.0500613102PubMed CentralView ArticlePubMedGoogle Scholar
- Ma L, Teruya-Feldstein J, Weinberg RA: Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 2007, 449: 682-688. 10.1038/nature06174View ArticlePubMedGoogle Scholar
- Medina PP, Nolde M, Slack FJ: OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature. 2010, 467: 86-90. 10.1038/nature09284View ArticlePubMedGoogle Scholar
- Kumar MS, Pester RE, Chen CY, Lane K, Chin C, Lu J, Kirsch DG, Golub TR, Jacks T: Dicer1 functions as a haploinsufficient tumor suppressor. Genes Dev. 2009, 23: 2700-2704. 10.1101/gad.1848209PubMed CentralView ArticlePubMedGoogle Scholar
- Karube Y, Tanaka H, Osada H, Tomida S, Tatematsu Y, Yanagisawa K, Yatabe Y, Takamizawa J, Miyoshi S, Mitsudomi T, Takahashi T: Reduced expression of Dicer associated with poor prognosis in lung cancer patients. Cancer Sci. 2005, 96: 111-115. 10.1111/j.1349-7006.2005.00015.xView ArticlePubMedGoogle Scholar
- Ting AH, Suzuki H, Cope L, Schuebel KE, Lee BH, Toyota M, Imai K, Shinomura Y, Tokino T, Baylin SB: A requirement for DICER to maintain full promoter CpG island hypermethylation in human cancer cells. Cancer Res. 2008, 68: 2570-2575. 10.1158/0008-5472.CAN-07-6405PubMed CentralView ArticlePubMedGoogle Scholar
- Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, Schmandt R, Urbauer D, Pennacchio LA, Cheng JF, Nick AM: Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med. 2008, 359: 2641-2650. 10.1056/NEJMoa0803785PubMed CentralView ArticlePubMedGoogle Scholar
- Nicklas W, Baneux P, Boot R, Decelle T, Deeny AA, Fumanelli M, Illgen-Wilcke B: Recommendations for the health monitoring of rodent and rabbit colonies in breeding and experimental units. Lab Anim. 2002, 36: 20-42. 10.1258/0023677021911740View ArticlePubMedGoogle Scholar
- Bjorkholm B, Lundin A, Sillen A, Guillemin K, Salama N, Rubio C, Gordon JI, Falk P, Engstrand L: Comparison of genetic divergence and fitness between two subclones of Helicobacter pylori. Infect Immun. 2001, 69: 7832-7838. 10.1128/IAI.69.12.7832-7838.2001PubMed CentralView ArticlePubMedGoogle Scholar
- Nilsson HO, Ouis IS, Stenram U, Ljungh A, Moran AP, Wadstrom T, Al-Soud WA: High prevalence of Helicobacter Species detected in laboratory mouse strains by multiplex PCR-denaturing gradient gel electrophoresis and pyrosequencing. J Clin Microbiol. 2004, 42: 3781-3788. 10.1128/JCM.42.8.3781-3788.2004PubMed CentralView ArticlePubMedGoogle Scholar
- Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J: Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004, 5: R80- 10.1186/gb-2004-5-10-r80PubMed CentralView ArticlePubMedGoogle Scholar
- Gregersen LH, Jacobsen AB, Frankel LB, Wen J, Krogh A, Lund AH: MicroRNA-145 targets YES and STAT1 in colon cancer cells. PLoS One. 2010, 5: e8836- 10.1371/journal.pone.0008836PubMed CentralView ArticlePubMedGoogle Scholar
- Jacobsen A, Wen J, Marks DS, Krogh A: Signatures of RNA binding proteins globally coupled to effective microRNA target sites. Genome Res. 2010, 20: 1010-1019. 10.1101/gr.103259.109PubMed CentralView ArticlePubMedGoogle Scholar
- Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N, Moskovits N, Bentwich Z, Oren M: Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell. 2007, 26: 731-743. 10.1016/j.molcel.2007.05.017View ArticlePubMedGoogle Scholar
- Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH, Feldmann G, Yamakuchi M, Ferlito M, Lowenstein CJ: Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell. 2007, 26: 745-752. 10.1016/j.molcel.2007.05.010PubMed CentralView ArticlePubMedGoogle Scholar
- He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, Xue W, Zender L, Magnus J, Ridzon D: A microRNA component of the p53 tumour suppressor network. Nature. 2007, 447: 1130-1134. 10.1038/nature05939PubMed CentralView ArticlePubMedGoogle Scholar
- Tarasov V, Jung P, Verdoodt B, Lodygin D, Epanchintsev A, Menssen A, Meister G, Hermeking H: Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle. 2007, 6: 1586-1593. 10.4161/cc.6.13.4436View ArticlePubMedGoogle Scholar
- Yamakuchi M, Ferlito M, Lowenstein CJ: miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci USA. 2008, 105: 13421-13426. 10.1073/pnas.0801613105PubMed CentralView ArticlePubMedGoogle Scholar
- Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ: Cancer statistics, 2006. CA Cancer J Clin. 2006, 56: 106-130. 10.3322/canjclin.56.2.106View ArticlePubMedGoogle Scholar
- Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer statistics, 2007. CA Cancer J Clin. 2007, 57: 43-66. 10.3322/canjclin.57.1.43View ArticlePubMedGoogle Scholar
- Shah MA, Kelsen DP: Gastric cancer: a primer on the epidemiology and biology of the disease and an overview of the medical management of advanced disease. J Natl Compr Canc Netw. 2010, 8: 437-447.PubMedGoogle Scholar
- Milne AN, Carneiro F, O'Morain C, Offerhaus GJ: Nature meets nurture: molecular genetics of gastric cancer. Hum Genet. 2009, 126: 615-628. 10.1007/s00439-009-0722-xPubMed CentralView ArticlePubMedGoogle Scholar
- Shiao YH, Rugge M, Correa P, Lehmann HP, Scheer WD: p53 alteration in gastric precancerous lesions. Am J Pathol. 1994, 144: 511-517.PubMed CentralPubMedGoogle Scholar
- Shibata A, Parsonnet J, Longacre TA, Garcia MI, Puligandla B, Davis RE, Vogelman JH, Orentreich N, Habel LA: CagA status of Helicobacter pylori infection and p53 gene mutations in gastric adenocarcinoma. Carcinogenesis. 2002, 23: 419-424. 10.1093/carcin/23.3.419View ArticlePubMedGoogle Scholar
- Wei J, Nagy TA, Vilgelm A, Zaika E, Ogden SR, Romero-Gallo J, Piazuelo MB, Correa P, Washington MK, El-Rifai W: Regulation of p53 Tumor Suppressor by Helicobacter pylori in Gastric Epithelial Cells. Gastroenterology. 2010, 139: 1333-1343. 10.1053/j.gastro.2010.06.018PubMed CentralView ArticlePubMedGoogle Scholar
- Jiaqing L, Hokita S, Xiangming C, Natsugoe S, Tanabe G, Baba M, Takao S, Aikou T: Role of cyclin E and p53 expression in progression of early gastric cancer. Gastric Cancer. 1998, 1: 160-165. 10.1007/s101200050011View ArticlePubMedGoogle Scholar
- Kouraklis G, Katsoulis IE, Theocharis S, Tsourouflis G, Xipolitas N, Glinavou A, Sioka C, Kostakis A: Does the expression of cyclin E, pRb, and p21 correlate with prognosis in gastric adenocarcinoma?. Dig Dis Sci. 2009, 54: 1015-1020. 10.1007/s10620-008-0464-yView ArticlePubMedGoogle Scholar
- Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, Sibley RK: Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med. 1991, 325: 1127-1131. 10.1056/NEJM199110173251603View ArticlePubMedGoogle Scholar
- Nomura A, Stemmermann GN, Chyou PH, Kato I, Perez-Perez GI, Blaser MJ: Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med. 1991, 325: 1132-1136. 10.1056/NEJM199110173251604View ArticlePubMedGoogle Scholar
- Shinozaki A, Sakatani T, Ushiku T, Hino R, Isogai M, Ishikawa S, Uozaki H, Takada K, Fukayama M: Downregulation of microRNA-200 in EBV-associated gastric carcinoma. Cancer Res. 2010, 70: 4719-4727. 10.1158/0008-5472.CAN-09-4620View ArticlePubMedGoogle Scholar
- Chen Y, Song Y, Wang Z, Yue Z, Xu H, Xing C, Liu Z: Altered expression of MiR-148a and MiR-152 in gastrointestinal cancers and its clinical significance. J Gastrointest Surg. 2010, 14: 1170-1179. 10.1007/s11605-010-1202-2View ArticlePubMedGoogle Scholar
- Tie J, Pan Y, Zhao L, Wu K, Liu J, Sun S, Guo X, Wang B, Gang Y, Zhang Y: MiR-218 inhibits invasion and metastasis of gastric cancer by targeting the Robo1 receptor. PLoS Genet. 2010, 6: e1000879- 10.1371/journal.pgen.1000879PubMed CentralView ArticlePubMedGoogle Scholar
- Tsukamoto Y, Nakada C, Noguchi T, Tanigawa M, Nguyen LT, Uchida T, Hijiya N, Matsuura K, Fujioka T, Seto M, Moriyama M: MicroRNA-375 is downregulated in gastric carcinomas and regulates cell survival by targeting PDK1 and 14-3-3zeta. Cancer Res. 2010, 70: 2339-2349. 10.1158/0008-5472.CAN-09-2777View ArticlePubMedGoogle Scholar
- Wan HY, Guo LM, Liu T, Liu M, Li X, Tang H: Regulation of the transcription factor NF-kappaB1 by microRNA-9 in human gastric adenocarcinoma. Mol Cancer. 2010, 9: 16- 10.1186/1476-4598-9-16PubMed CentralView ArticlePubMedGoogle Scholar
- Kim MS, Oh JE, Kim YR, Park SW, Kang MR, Kim SS, Ahn CH, Yoo NJ, Lee SH: Somatic mutations and losses of expression of microRNA regulation-related genes AGO2 and TNRC6A in gastric and colorectal cancers. J Pathol. 2010, 221: 139-146. 10.1002/path.2683View ArticlePubMedGoogle Scholar
- Zhou H, Guo JM, Lou YR, Zhang XJ, Zhong FD, Jiang Z, Cheng J, Xiao BX: Detection of circulating tumor cells in peripheral blood from patients with gastric cancer using microRNA as a marker. J Mol Med. 2010, 88: 709-717. 10.1007/s00109-010-0617-2View ArticlePubMedGoogle Scholar
- Ueda T, Volinia S, Okumura H, Shimizu M, Taccioli C, Rossi S, Alder H, Liu CG, Oue N, Yasui W: Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol. 2010, 11: 136-146. 10.1016/S1470-2045(09)70343-2PubMed CentralView ArticlePubMedGoogle Scholar
- Tsujiura M, Ichikawa D, Komatsu S, Shiozaki A, Takeshita H, Kosuga T, Konishi H, Morimura R, Deguchi K, Fujiwara H: Circulating microRNAs in plasma of patients with gastric cancers. Br J Cancer. 2010, 102: 1174-1179. 10.1038/sj.bjc.6605608PubMed CentralView ArticlePubMedGoogle Scholar
- Yang X, Feng M, Jiang X, Wu Z, Li Z, Aau M, Yu Q: miR-449a and miR-449b are direct transcriptional targets of E2F1 and negatively regulate pRb-E2F1 activity through a feedback loop by targeting CDK6 and CDC25A. Genes Dev. 2009, 23: 2388-2393. 10.1101/gad.1819009PubMed CentralView ArticlePubMedGoogle Scholar
- Noonan EJ, Place RF, Pookot D, Basak S, Whitson JM, Hirata H, Giardina C, Dahiya R: miR-449a targets HDAC-1 and induces growth arrest in prostate cancer. Oncogene. 2009, 28: 1714-1724. 10.1038/onc.2009.19View ArticlePubMedGoogle Scholar
- Wu W, Lin Z, Zhuang Z, Liang X: Expression profile of mammalian microRNAs in endometrioid adenocarcinoma. Eur J Cancer Prev. 2009, 18: 50-55. 10.1097/CEJ.0b013e328305a07aView ArticlePubMedGoogle Scholar
- Jukic DM, Rao UN, Kelly L, Skaf JS, Drogowski LM, Kirkwood JM, Panelli MC: Microrna profiling analysis of differences between the melanoma of young adults and older adults. J Transl Med. 2010, 8: 27- 10.1186/1479-5876-8-27PubMed CentralView ArticlePubMedGoogle Scholar
- Greco S, De Simone M, Colussi C, Zaccagnini G, Fasanaro P, Pescatori M, Cardani R, Perbellini R, Isaia E, Sale P: Common micro-RNA signature in skeletal muscle damage and regeneration induced by Duchenne muscular dystrophy and acute ischemia. FASEB J. 2009, 23: 3335-3346. 10.1096/fj.08-128579View ArticlePubMedGoogle Scholar
- Lize M, Pilarski S, Dobbelstein M: E2F1-inducible microRNA 449a/b suppresses cell proliferation and promotes apoptosis. Cell Death Differ. 2009, 17: 452-458. 10.1038/cdd.2009.188View ArticlePubMedGoogle Scholar
- Feng M, Yu Q: miR-449 regulates CDK-Rb-E2F1 through an auto-regulatory feedback circuit. Cell Cycle. 2010, 9: 213-214. 10.4161/cc.9.2.10502View ArticlePubMedGoogle Scholar
- Welch C, Chen Y, Stallings RL: MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene. 2007, 26: 5017-5022. 10.1038/sj.onc.1210293View ArticlePubMedGoogle Scholar
- Lodygin D, Tarasov V, Epanchintsev A, Berking C, Knyazeva T, Korner H, Knyazev P, Diebold J, Hermeking H: Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle. 2008, 7: 2591-2600. 10.4161/cc.7.16.6533View ArticlePubMedGoogle Scholar
- Christoffersen NR, Shalgi R, Frankel LB, Leucci E, Lees M, Klausen M, Pilpel Y, Nielsen FC, Oren M, Lund AH: p53-independent upregulation of miR-34a during oncogene-induced senescence represses MYC. Cell Death Differ. 2010, 17: 236-245. 10.1038/cdd.2009.109View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.